Analystreport

NGM Biopharmaceuticals (NYSE: NGM) is now covered by analysts at Raymond James. They set a "strong-buy" rating on the stock.

NGM Biopharmaceuticals, Inc.  (NGM) 
Last ngm biopharmaceuticals, inc. earnings: 3/17 04:05 pm Check Earnings Report